Presentation is loading. Please wait.

Presentation is loading. Please wait.

Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment  Laura Van Gerven, MD, PhD, Yeranddy.

Published byLeona van der Zee Modified over 6 years ago

Similar presentations

Presentation on theme: "Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment  Laura Van Gerven, MD, PhD, Yeranddy."— Presentation transcript:

1 Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment  Laura Van Gerven, MD, PhD, Yeranddy A. Alpizar, PhD, Brecht Steelant, PhD, Ina Callebaut, PhD, Inge Kortekaas Krohn, MSc, Mira Wouters, PhD, François Vermeulen, MD, Guy Boeckxstaens, MD, PhD, Karel Talavera, PhD, Peter W. Hellings, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 2, Pages e2 (August 2017) DOI: /j.jaci Copyright © Terms and Conditions

2 Fig 1 Baseline NMP measurements in HC subjects and patients with IR. A and B, Representative experiments of NMP recordings during exposure to AITC in an HC subject (Fig 1, A) and a patient with IR (Fig 1, B). C, Distribution of HC subjects and patients with IR according to the concentration threshold for NMP responses to AITC. D, Distribution of patients with IR with and without NHR according to the concentration threshold for NMP responses to AITC. *P < .05. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

3 Fig 2 Response of patients with IR to capsaicin and placebo treatments. A and B, Average TSSs (Fig 2, A) and average VAS scores for major symptoms at baseline and at 4, 12, and 26 weeks after capsaicin or placebo treatment in patients with IR (n = 24 and n = 9, respectively). C-F, Average VAS scores for individual symptoms at 4, 12, and 26 weeks after capsaicin or placebo treatment in patients with IR. The maximum of the scale for TSSs and VAS scores for major symptom/individual symptoms were 40 and 10 cm, respectively. *P < .05 and **P < .005. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

4 Fig 3 Distribution of TREs at 4, 12, and 26 weeks after capsaicin (Caps) or placebo treatment in relation to baseline. *P < .05 and **P < .005. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

5 Fig 4 Distribution of the capsaicin- and placebo-treated patients according to their threshold for the NMP responses to AITC determined at baseline and at 4, 12, and 26 weeks after treatment. *P < .05. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

6 Fig 5 Capsaicin treatment decreases the sensitivity to AITC in patients with IR in parallel with nasal symptoms. A and B, Correlation between change in threshold for NMP responses to AITC and changes in TSSs (Fig 5, A) and VAS scores for major symptoms (Fig 5, B) determined 4 weeks after capsaicin treatment. C and D, Examples of NMP responses to AITC recorded in a patient with IR before (Fig 5, C) and 4 weeks after (D-F) capsaicin treatment. Note the sharp negative deflection of the trace in response to application of 5 mmol/L AITC before treatment, and the lack of such a response 4 weeks after treatment even at 20 mmol/L AITC. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

7 Fig 6 Therapeutic response of patients with IR 12 weeks after capsaicin/placebo treatment. Distribution of the therapeutic response of patients when classified according to the presence of NHR (A) or the concentration threshold for the NMP response to AITC determined at baseline (B) is shown. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

8 Fig 7 TRPV1 expression in HC subjects and patients with IR at baseline and in relation to the therapeutic response. A, TRPV1 mRNA expression (RT-PCR) in homogenates of nasal biopsy specimens in HC subjects and patients with IR at baseline. The IR group is subdivided into patients with IR with and without NHR. B, Relation between baseline TRPV1 mRNA expression in patients with IR and the therapeutic response 12 weeks after capsaicin treatment. *P < .05 and ***P < .0005. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

9 Fig E1 Illustration of the multichannel aerosol.
Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © Terms and Conditions

Download ppt "Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment  Laura Van Gerven, MD, PhD, Yeranddy."

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
The K+ channel iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells  S Mark Duffy, PhD, Patrick Berger, MD, PhD, Glenn Cruse, Weidong.

The K+ channel iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells  S Mark Duffy, PhD, Patrick Berger, MD, PhD, Glenn Cruse, Weidong.
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Role of nasal nitric oxide in the resolution of experimental rhinovirus infection  Scherer P Sanders, PhD, David Proud, PhD, Solbert Permutt, MD, Edward.

Role of nasal nitric oxide in the resolution of experimental rhinovirus infection  Scherer P Sanders, PhD, David Proud, PhD, Solbert Permutt, MD, Edward.
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression 

Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Brecht Steelant, PhD, Sven F

Brecht Steelant, PhD, Sven F
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Similar presentations

Ads by Google